In this podcast, we will discuss recent developments in radioligand therapy for metastatic castration-resistant prostate cancer (mCRPC) treatment, as part one of our series for Prostate Cancer Awareness Month. Listen to leading experts as they share breakthroughs in mCRPC research.

First, Omid Yazdanpanah, MD, from the University of California, shares findings from the VISION trial, which assessed 177Lu-PSMA-617 with or without androgen receptor pathway inhibitors (ARPIs) in patients with mCRPC, as well as the potential of radioligands with ARPIs in in the ENZA-p trial. Andrei Gafita, MD, from Johns Hopkins Medicine, subsequently discusses the significance of post-therapy LuPSMA-SPECT/CT in patients with mCRPC and Umang Swami, MD, MS, from the University of Utah, gives an overview of findings from the PRO-XL trial. Michael Morris, from Memorial Sloan Kettering Cancer Center, ends the podcast by addressing the challenges in using radioligand therapy for patients with mCRPC.